Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine
- PMID: 22353673
- DOI: 10.1016/j.vaccine.2012.02.013
Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine
Abstract
Persistence of antibodies after a single dose of Tdap vaccine (tetanus, diphtheria, and 5-component acellular pertussis vaccine) was evaluated in a follow-up study of adolescents (N=324) and adults (N=644) who had received Tdap in earlier clinical trials. Outcome measures were seroprotection (tetanus and diphtheria) or seropositivity (pertussis) and geometric mean concentrations. Humoral immune responses to all antigens were robust 1 month after initial immunization, decreased at subsequent measurements, but continued to exceed pre-immunization levels 1, 3, 5, and 10 years later. Protective levels of diphtheria and tetanus antitoxin persisted in 99.3% of adolescents 10 years after a booster dose of Tdap. Seropositivity to 1 or more pertussis antigens also persisted in most adolescents for 10 years. Although tetanus antitoxin responses were similar in adults to those observed in adolescents, diphtheria antitoxin titers were lower, reflecting the fact that a smaller proportion of adults had received diphtheria toxoid in the previous 10 years compared to adolescents. These data will contribute to the selection of the optimal interval for repeat doses of Tdap.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine.Vaccine. 2007 Nov 23;25(48):8172-9. doi: 10.1016/j.vaccine.2007.09.031. Epub 2007 Oct 2. Vaccine. 2007. PMID: 17945400
-
Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.Drugs. 2012 Sep 10;72(13):1765-91. doi: 10.2165/11209630-000000000-00000. Drugs. 2012. PMID: 22931522 Review.
-
Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA.Vaccine. 2018 Apr 19;36(17):2282-2287. doi: 10.1016/j.vaccine.2018.03.029. Epub 2018 Mar 21. Vaccine. 2018. PMID: 29573876
-
A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.Vaccine. 2012 Aug 10;30(37):5464-71. doi: 10.1016/j.vaccine.2012.06.073. Epub 2012 Jul 6. Vaccine. 2012. PMID: 22776216 Clinical Trial.
-
Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.BioDrugs. 2009;23(4):253-67. doi: 10.2165/11202770-000000000-00000. BioDrugs. 2009. PMID: 19697967 Review.
Cited by
-
Generating enhanced mucosal immunity against Bordetella pertussis: current challenges and new directions.Front Immunol. 2023 Feb 21;14:1126107. doi: 10.3389/fimmu.2023.1126107. eCollection 2023. Front Immunol. 2023. PMID: 36895562 Free PMC article.
-
Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines.EClinicalMedicine. 2021 Jun 23;37:100976. doi: 10.1016/j.eclinm.2021.100976. eCollection 2021 Jul. EClinicalMedicine. 2021. PMID: 34386749 Free PMC article.
-
ERRATA CORRIGE.J Prev Med Hyg. 2021 Apr 29;62(1):E249-E260. doi: 10.15167/2421-4248/jpmh2021.62.1.1832. eCollection 2021 Mar. J Prev Med Hyg. 2021. PMID: 34322644 Free PMC article.
-
Pertactin-Deficient Bordetella pertussis, Vaccine-Driven Evolution, and Reemergence of Pertussis.Emerg Infect Dis. 2021 Jun;27(6):1561-1566. doi: 10.3201/eid2706.203850. Emerg Infect Dis. 2021. PMID: 34014152 Free PMC article. Review.
-
Immunogenicity and antibody persistence of diphteria-tetanus-acellular pertussis vaccination in adolescents and adults: a systematic review of the literature showed different responses to the available vaccines.J Prev Med Hyg. 2021 Jan 14;61(4):E530-E541. doi: 10.15167/2421-4248/jpmh2020.61.4.1832. eCollection 2020 Dec. J Prev Med Hyg. 2021. PMID: 33628957 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical